RxDoctor Payments Data

Adam Ulibarri, MD

Family Medicine · Albuquerque, NMNPI 1043744824

Payments from drug & device makers

$782in general payments, 2019–2025

Across 38 payments — averaging $20.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$359
  • Novo Nordisk$113
  • Lilly USA, LLC$38
  • Exact Sciences$37
  • Novartis$35
  • GSK$32
  • plus $168 from 8 others

What the payments were for

  • Food & beverage$782100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$782 in reported general payments places this provider in the 75th percentile of 717 family medicine providers in New Mexico.

See all family medicine providers in New Mexico

Medicare billing

Part B allowed, 2024
$40,512
Medicare patients
159
Services billed
711

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin122$160,691
TrulicityDulaglutide59$93,787
OzempicSemaglutide33$78,507
RybelsusSemaglutide30$57,390
EliquisApixaban50$56,847
CreonLipase/Protease/Amylase18$43,281
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$31,782
MyrbetriqMirabegron26$25,159
MounjaroTirzepatide11$22,696
XareltoRivaroxaban14$16,025
Victoza 3-PakLiraglutide14$14,652
Fluticasone-SalmeterolFluticasone Propion/Salmeterol34$9,641
Serevent DiskusSalmeterol Xinafoate18$8,458
Atorvastatin Calcium621$8,018
Levothyroxine Sodium523$7,791

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$359$160,691122 claims
Novo NordiskOzempic, Rybelsus$113$135,89763 claims
Lilly USA, LLCTrulicity, Mounjaro$38$116,48370 claims
PfizerEliquis$32$56,84750 claims
GSKTrelegy Ellipta, Anoro Ellipta$32$38,28440 claims
Johnson & JohnsonXarelto$17$16,02514 claims
AstraZenecaSymbicort$18$5,09213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 717 family medicine providers in New Mexico.

Other family medicine in Albuquerque

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →